Claims
- 1. A method of reducing incidence of renal flares in a systemic lupus erythematosus patient having significantly impaired renal function, comprising administering to the patient an effective amount of a conjugate comprising a non-immunogenic valency platform molecule and two or more double stranded DNA (dsDNA) epitopes, wherein the double stranded DNA epitopes are polynucleotides.
- 2. The method of claim 1, wherein the polynucleotides are double stranded DNA.
- 3. The method of claim 2, wherein said polynucleotides comprise the sequence 5′-GTGTGTGTGTGTGTGTGTGT-3′.
- 4. The method of claim 3, wherein the platform molecule is
- 5. The method of claim 1, wherein said patient has serum creatinine of greater than 1.5 milligrams per deciliter (mg/dL).
- 6. A method of treating systemic lupus erythematosus (SLE) in an individual, comprising selecting an individual having SLE and significantly impaired renal function, and administering to the individual an effective amount of a conjugate comprising a non-immunogenic valency platform molecule and two or more double stranded DNA (dsDNA) epitopes, wherein the dsDNA epitopes are polynucleotides.
- 7. The method of claim 6, wherein the polynucleotides are double stranded DNA.
- 8. The method of claim 7, wherein said polynucleotides comprise the sequence 5′-GTGTGTGTGTGTGTGTGTGT-3′.
- 9. The method of claim 8, wherein said polynucleotides consist essentially of the sequence 5′-GTGTGTGTGTGTGTGTGTGT-3′.
- 10. The method of claim 9, wherein the polynucleotide consists of the sequence 5′-GTGTGTGTGTGTGTGTGTGT-3′.
- 11. The method of claim 10, wherein the platform molecule is
- 12. The method of claims 1 or 6, wherein before or upon initiation of treatment the individual comprises antibodies having an apparent equilibrium dissociation constant (KD′) for a polynucleotide of the conjugate of less than about 1.0 mg IgG per mL.
- 13. The method of claim 12, wherein the KD′ is less than about 0.8.
- 14. The method of claim 12, wherein the KD′ is less than about 0.5.
- 15. The method of claim 12, wherein the KD′ is less than about 0.2.
- 16. The method of claims 1 or 6, wherein affinity of antibodies from the individual for a polynucleotide of the conjugate is assessed.
- 17. The method of claim 16, wherein said affinity is assessed prior to or upon initiation of treatment of the individual, thereby producing an initial affinity measurement.
- 18. The method of claim 17, wherein the initial affinity measurement is an apparent equilibrium dissociation constant (KD′).
- 19. The method of claim 18, wherein the KD′ is less than about 1.0 mg IgG per mL.
- 20. The method of claim 18, wherein the KD′ is less than about 0.8.
- 21. The method of claim 18, wherein the KD′ is less than about 0.5.
- 22. The method of claim 6, wherein the platform molecule is
- 23. The method of claim 6 wherein the conjugate is administered in an amount effective to reduce incidence of renal flares in the individual.
- 24. The method of claims 1 or 6, wherein a medication selected from the group consisting of corticosteroids and cyclophosphamide is also administered to the individual.
- 25. The method of claim 24 wherein the conjugate is administered in an amount effective to reduce the amount of a corticosteroid or cyclophosphamide administered to the individual.
- 26. The method of claims 1 or 6, wherein the individual is human.
- 27. A method of treating systemic lupus erythematosus (SLE) in an individual, comprising selecting an individual having (a) SLE, (b) significantly impaired renal function, and (c) antibodies with high affinity to a polynucleotide epitope a conjugate comprising a non-immunogenic valency platform molecule and two or more polynucleotides, said polynucleotides comprisine at least one double stranded DNA epitope, and administering to the individual an effective amount of said conjugate.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority under 35 U.S.C §119(e) to U.S. Provisional Patent Application Serial No. 60/311,858, filed Aug. 13, 2001, and to U.S. Provisional Patent Application Serial No. 60/314,281, filed Aug. 22, 2001, each of which is hereby incorporated by reference in its entirety.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60311858 |
Aug 2001 |
US |
|
60314281 |
Aug 2001 |
US |